APA
PRQR icon

American Portfolios Advisors’s ProQR Therapeutics PRQR Stock Holding History

American Portfolios Advisors’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-21
Closed -$291 – 2780
2019
Q1 		$291 Buy
+21
New +$314 ﹤0.01% 2557

Other funds holding PRQR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
HSBC Holdings
HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return

American Portfolios Advisors's PRQR Position: Q2 2019 in Review

American Portfolios Advisors sold out of ProQR Therapeutics (PRQR) in Q2 2019, closing a stake of 21 shares — an estimated $291 sold.

American Portfolios Advisors first reported a position in PRQR in Q1 2019 and held it in 1 quarter. The position peaked at $291 in Q1 2019. 55 funds tracked by Wall St. Rank hold PRQR as of Q2 2019.

  • American Portfolios Advisors reported no remaining ProQR Therapeutics position as of Q2 2019 after selling out during the quarter.
  • American Portfolios Advisors sold 21 ProQR Therapeutics shares in Q2 2019, an estimated $291.
  • American Portfolios Advisors first reported a position in ProQR Therapeutics in Q1 2019 and held it in 1 quarter.
  • American Portfolios Advisors's ProQR Therapeutics position peaked at $291 in Q1 2019.
  • 55 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q2 2019.

Based on American Portfolios Advisors's 13F filing for Q2 2019, filed 24 Mar 2023.